Amanote Research
Register
Sign In
Recommendations for the Prevention of Streptococcus Pneumoniae Infections in Infants and Children: Use of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) and Pneumococcal Polysaccharide Vaccine (PPSV23)
Pediatrics
- United States
doi 10.1542/peds.2010-1280
Full Text
Open PDF
Abstract
Available in
full text
Categories
Child Health
Pediatrics
Perinatology
Date
May 24, 2010
Authors
Unknown
Publisher
American Academy of Pediatrics (AAP)
Related search
Policy Statement: Recommendations for the Prevention of Pneumococcal Infections, Including the Use of Pneumococcal Conjugate Vaccine (Prevnar), Pneumococcal Polysaccharide Vaccine, and Antibiotic Prophylaxis
Pediatrics
Child Health
Pediatrics
Perinatology
Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices
MMWR. Morbidity and mortality weekly report
Health Information Management
Mutagenesis
Epidemiology
Health
Medicine
Toxicology
Clinical Efficacy of Pneumococcal Conjugate 13-Valent Vaccine in Young Children
Pediatric pharmacology
The 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Elicits Cross-Functional Opsonophagocytic Killing Responses in Humans to Streptococcus Pneumoniae Serotypes 6C and 7A
Vaccine
Molecular Medicine
Public Health
Veterinary
Microbiology
Environmental
Immunology
Infectious Diseases
Occupational Health
Introduction of the 13-Valent Pneumococcal Conjugate Vaccine in an Isolated Pneumococcal Vaccine-Naïve Indigenous Population
European Respiratory Journal
Medicine
Pulmonary
Respiratory Medicine
Public and Private Payer Perspectives on the Net Cost of Implementation of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Compared With 7-Valent Pneumococcal Conjugate Vaccine (PCV7) to in the United States
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Immunogenicity and Tolerance of a 7-Valent Pneumococcal Conjugate Vaccine in Nonresponders to the 23-Valent Pneumococcal Vaccine
Infection and Immunity
Parasitology
Infectious Diseases
Immunology
Microbiology
PIN64 Assessing the Cost-Effectiveness (CE) of Vaccinating the Elderly and At-Risk Adults With the 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23) Compared to the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) or No Vaccination (NoVac) in the UK
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Postlicensure Safety Surveillance for 7-Valent Pneumococcal Conjugate Vaccine
JAMA - Journal of the American Medical Association
Medicine
